Repatha (Evolocumab) Missed-Dose Protocol: What to Do and When

Evolocumab (brand name Repatha, Amgen) is a fully human monoclonal antibody in the PCSK9-inhibitor class, given by subcutaneous injection. It is FDA-approved as an adjunct to diet, alone or with other lipid-lowering therapies (including statins), for adults with primary hyperlipidemia or established atherosclerotic cardiovascular disease, and for certain patients with homozygous or heterozygous familial hypercholesterolemia, including some pediatric patients age 10 and older. It should not be confused with alirocumab (Praluent), the other approved PCSK9 monoclonal antibody, or with inclisiran (Leqvio), a small-interfering-RNA agent with a different mechanism and a much longer dosing interval.

The core, quotable answer: the FDA label for Repatha specifies a 7-day missed-dose window that applies identically to both approved schedules; inside that window the patient injects immediately and stays on the original calendar, and outside it the patient skips straight to the next scheduled dose without doubling up. This rule reflects the drug's long half-life rather than a fixed clinical trial protocol, and a single missed dose has not been shown to cause a clinically important cardiovascular setback when the schedule is resumed promptly. What has not been established with the same confidence is the effect of repeated or clustered missed doses on long-term outcomes, which is why the discussion below treats "occasional lapse" and "recurring nonadherence" as two different problems.

Why the 7-day cutoff exists

Evolocumab has a terminal half-life of roughly 11 to 17 days at steady state. A dose given within about a week of the missed date still falls inside a period where circulating drug levels remain within a useful range, so injecting late captures most of the intended effect. Past that point, the FDA label directs patients to wait for the next scheduled dose rather than inject two doses closer together than labeled, because evolocumab's target-binding mechanism is saturable: once available PCSK9 is bound, additional drug does not produce proportionally more LDL receptor recycling or additional LDL-C lowering. Practically, doubling up trades a small, unproven benefit for a real cost (an extra expensive injection and unnecessary injection-site exposure) without a clear clinical upside.

This information is drawn from the FDA-approved prescribing information. Readers who need the exact current wording, including the most recent label revision, should confirm against the FDA label directly, since revision numbers change over time.

What is established, what is plausible, and what is not established

• Established (label-level): the 7-day missed-dose rule, the two approved dosing options (140 mg every 2 weeks or 420 mg monthly), the drug's mechanism as a PCSK9-binding monoclonal antibody, and the absence of a need for dose adjustment in mild-to-moderate renal or hepatic impairment.
• Plausible but not rigorously quantified on this page: the exact magnitude and time course of LDL-C rebound after a single missed dose. Pharmacokinetic reasoning and general clinical experience with long-half-life biologics suggest a partial, transient rise rather than a full return to pretreatment LDL-C, but a precise number (for example, "30 to 50 mg/dL") should be verified against the primary pharmacology literature before it is used in patient counseling, and it will vary by individual baseline and background therapy.
• Not established from the material available here: any claim that occasional single missed doses measurably change hard cardiovascular outcomes. The pivotal outcomes trial for evolocumab (FOURIER, Sabatine et al., New England Journal of Medicine, 2017) demonstrated a reduction in major adverse cardiovascular events with sustained evolocumab therapy added to statin treatment, but conclusions about isolated missed doses specifically require checking the trial's adherence/sensitivity analyses in the original publication rather than assuming a straight-line relationship between one missed injection and event risk.

FOURIER and the broader case for sustained dosing

FOURIER enrolled a large population of adults with established atherosclerotic cardiovascular disease already on statin therapy and randomized them to evolocumab or placebo. The trial reported a meaningful relative reduction in the composite of cardiovascular death, myocardial infarction, stroke, and related events over roughly two years of follow-up, alongside a large reduction in LDL-C compared with placebo. These are widely reported topline findings; readers who need exact percentages, confidence intervals, or subgroup results for clinical decision-making should pull the original NEJM publication rather than relying on secondhand figures, since exact numbers were not independently re-verified for this draft.

The trial's broader message for this page is straightforward: evolocumab's cardiovascular benefit comes from sustained, cumulative LDL-C lowering over months to years, not from any single injection. A missed-dose protocol exists precisely to prevent an occasional lapse from becoming a pattern of nonadherence, which is the scenario more plausibly linked to attenuated benefit.

A different clinical context: evolocumab timing around acute MI

Separate from routine missed-dose management, researchers have also studied when to first give evolocumab relative to an acute event. The AMUNDSEN trial, registered to evaluate evolocumab administered before percutaneous coronary intervention for acute myocardial infarction, is examining whether earlier initiation around an acute coronary event changes outcomes (trial design, 2026). This is a distinct clinical question from what to do about a missed maintenance dose in a stable outpatient, and its results, once published, should not be assumed to apply to routine missed-dose timing for patients already established on therapy. It is included here only so readers researching evolocumab do not conflate "initiation timing in acute MI" with the outpatient missed-dose rule that is the subject of this page.

Biweekly vs. monthly: does the schedule change the missed-dose risk?

Both FDA-approved regimens, 140 mg every 2 weeks and 420 mg monthly, are intended to produce comparable steady-state LDL-C lowering, and the missed-dose rule is identical for each. The practical tradeoff is behavioral rather than pharmacologic: biweekly dosing means more frequent injections but a smaller single-injection burden, while monthly dosing consolidates the task into three sequential 140 mg injections (or one on-body infusor session) less often. Neither schedule has been shown on this page's evidence to produce meaningfully different real-world adherence; the more useful question for an individual patient is which schedule fits their routine well enough that a missed dose becomes rare, and that is a conversation for the prescribing clinician rather than a generic rule.

Practical steps after a missed dose

1. Confirm the due date, not the last injection date. Count days from when the dose was scheduled, not from the prior injection.
2. If fewer than 7 days late, administer the injection using standard technique (thigh, abdomen, or upper arm), then return to the original calendar for the next dose. Do not shift the whole schedule forward.
3. If 7 or more days late, skip the missed dose and wait for the next regularly scheduled date.
4. If it is unclear whether a dose was actually given (partial expulsion from the syringe, uncertainty about whether an injection occurred), contact the prescriber before re-dosing rather than guessing. An unnecessary extra dose is unlikely to cause harm but wastes an expensive medication.
5. Set a recurring reminder. Manufacturer patient-support programs, pharmacy apps, and simple calendar alerts all reduce the chance of a second lapse.

Switching between dosing schedules

The FDA label allows switching between the biweekly and monthly regimens without a washout period. To move from every-2-weeks to monthly, the first 420 mg dose is given on the date the next 140 mg dose would have been due. To move from monthly to every-2-weeks, the first 140 mg dose is given on the date the next 420 mg dose would have been due. Because prior authorization and syringe quantities on file with a pharmacy or insurer often depend on which regimen is prescribed, the prescriber should be informed before a patient switches, even though the clinical transition itself does not require special monitoring.

Storage and a compromised dose

Repatha prefilled syringes and autoinjectors require refrigeration at 2°C to 8°C (36°F to 46°F). A single carton may be kept at room temperature, up to 25°C (77°F), for a limited period specified on the current label; once removed from the refrigerator, it should not be returned to cold storage. If a dose was left out longer than the labeled room-temperature allowance, or was exposed to temperatures outside the labeled range, it should be discarded rather than injected, and a replacement requested from the pharmacy. Confirm the exact current allowable room-temperature duration against the label rather than assuming a fixed number, since storage guidance can be revised.

Special populations

Homozygous familial hypercholesterolemia (HoFH). Evolocumab is approved for HoFH at 420 mg monthly. Response is reduced in patients with two nonfunctional LDL receptor alleles, because the drug's mechanism depends on rescuing existing receptor recycling. The missed-dose rule does not change for this population, but a patient with a markedly attenuated baseline response may notice less apparent LDL-C swing around a missed dose simply because their overall response is smaller.

Heterozygous familial hypercholesterolemia (HeFH) and pediatric patients age 10 and older. The missed-dose protocol is the same as in adults with atherosclerotic disease. Caregivers of pediatric patients should be walked through the 7-day rule at the initial prescribing visit, since a young patient may not reliably track injection dates independently.

Renal or hepatic impairment. No dose adjustment is required for mild-to-moderate impairment, since evolocumab is cleared by proteolytic degradation rather than renal or hepatic metabolism, and the missed-dose window does not change for these patients.

Drug interactions and the missed-dose question

Evolocumab is not known to have clinically significant pharmacokinetic drug-drug interactions. Statins, ezetimibe, fibrates, and bile acid sequestrants can generally be continued on their usual schedule regardless of whether an evolocumab injection is on time. A missed evolocumab dose is not, by itself, a reason to change statin intensity; if a clinician is considering intensifying background lipid therapy because of a lapse in evolocumab dosing, that decision should weigh the individual's overall cardiovascular risk and recent lipid values rather than the missed dose alone.

A clinician-discussion and monitoring framework for missed doses

This framework is meant to structure a conversation with a prescriber or pharmacist, not to replace one. It distinguishes what the label settles from what requires individualized judgment.

Checkpoint 1: Was this a single, isolated lapse or a pattern?

• Label guidance covers the single lapse clearly (7-day rule above).
• A pattern (two or more missed doses in a 6-month period, or repeated late doses) moves outside simple label mechanics and into an adherence-and-access conversation: cost, injection anxiety, forgetting, or a schedule mismatch with the patient's routine. This is a site-judgment / individualized-care question, not something a fixed rule resolves.

Checkpoint 2: How many consecutive doses were missed?

• One dose within the 7-day window: follow the label rule, no lipid recheck needed.
• One dose beyond 7 days, isolated: follow the label rule (skip, resume next scheduled dose); a lipid panel is reasonable at the next routine visit but not urgent.
• Two or more consecutive doses missed, or a gap of a month or more with no injection: this is a reasonable trigger to contact the prescriber before simply resuming, since the degree of LDL-C rebound and the right way to restart (same dose vs. reassessment) is individualized and not fully specified by the label.

Checkpoint 3: Is there uncertainty about whether a dose was actually given?

• If a patient cannot confirm whether an injection was completed (partial syringe expulsion, device malfunction, memory uncertainty), the safe default is to contact the prescriber rather than re-dose speculatively. Re-injecting "just in case" is a judgment call that a general protocol cannot make safely for an individual.

Checkpoint 4: Are there symptoms that change the picture?

• New injection-site reactions, signs of an allergic response (hives, facial or throat swelling, difficulty breathing), or chest pain/shortness of breath are not "missed-dose" issues and warrant urgent evaluation regardless of dosing schedule. A missed dose does not need to be resolved before seeking urgent care for these symptoms.

Checkpoint 5: Does the schedule itself need to change?

• If missed doses are recurring, switching between biweekly and monthly dosing, enrolling in a manufacturer reminder or support program, or addressing an access/cost barrier are reasonable topics to raise, but the choice among them depends on the individual's routine and insurance situation, which this page cannot assess.

Where the label stops and individualized care begins: the label defines the mechanical missed-dose rule (7 days) and the switching procedure. It does not define how to manage recurring nonadherence, how aggressively to recheck lipids after a lapse, or how to weigh a missed dose against other cardiovascular risk factors in a given patient. Those decisions belong to the prescribing clinician.

When to seek urgent care rather than follow this protocol

A missed injection is not a medical emergency by itself. Seek urgent evaluation instead of following the missed-dose steps above if a patient experiences chest pain, sudden shortness of breath, one-sided weakness or facial drooping, or signs of a severe allergic reaction (facial or throat swelling, widespread hives, difficulty breathing) after any injection, whether or not the dose was on schedule.